Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil

被引:28
作者
Lidgate, D [1 ]
Brandl, M [1 ]
Holper, M [1 ]
Abubakari, A [1 ]
Wu, XY [1 ]
机构
[1] Roche Biosci, Palo Alto, CA 94304 USA
关键词
mycophenolate mofetil; mycophenolic acid; ferrous sulfate; interaction;
D O I
10.1081/DDC-120015361
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Studies were performed to (1) evaluate whether the presence of iron affected the physicochemical properties of mycophenolate mofetil (MMF) and mycophenolic acid (MPA), and (2) determine whether alteration of these properties was indicative of formation of an MMF-iron complex. The solubility, stability (chemical reactivity), and partitioning properties of MMF and MPA were evaluated over a pH range of 2-7 in the presence and absence of ferrous sulfate. In addition, the solubility and partitioning properties of MMF were assessed after the MMF drug product, CellCept(R) capsules, was combined with an iron tablet (Fero-Gradumet(R), ferrous sulfate, tablets). The results of studies showed that: The solubility of MMF in the presence of ferrous sulfate was generally unaffected over a pH range of 2-7; a small increase in solubility was observed in pH 5.2 buffer solution. The solubility of MPA decreased in pH 5.2 and 7.0 buffer solutions. Both MMF and MPA were more stable in the presence of ferrous sulfate at pH 2.0; ferrous sulfate had no effect on the stability of MMF and MPA at pH 7.0. Overall, the partitioning of MMF and MPA was unaffected by the addition of ferrous sulfate. The solubility and partitioning of MMF from CellCept(R) capsules combined with Fero-Gradumet(R) (ferrous sulfate) tablets showed a twofold increase in aqueous solubility of MMF as well as increased concentration of MMF in both the n-octanol and aqueous phases, leading to a decrease in the octanol/water partition coefficient due to a reduction in pH of the aqueous phase. Based on these results, it was concluded that the physicochemical properties of MMF and MPA were generally not affected by the presence of ferrous sulfate. Further, the presence of ferrous sulfate did not suggest the formation of an MMF iron complex.
引用
收藏
页码:1275 / 1283
页数:9
相关论文
共 11 条
[1]   Clinical pharmacokinetics of mycophenolate mofetil [J].
Bullingham, RES ;
Nicholls, AJ ;
Kanmm, BR .
CLINICAL PHARMACOKINETICS, 1998, 34 (06) :429-455
[2]  
D'ARCY P F, 1985, Reviews on Drug Metabolism and Drug Interactions, V5, P83
[3]  
DARCY PF, 1982, MET IONS BIOL SYST, P1
[4]  
GRINYO J, 1995, LANCET, V345, P1321
[5]   Degradation products of mycophenolate mofetil in aqueous solution [J].
Hooijmaaijer, E ;
Brandl, M ;
Nelson, J ;
Lustig, D .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (03) :361-365
[6]  
Keown P, 1996, TRANSPLANTATION, V61, P1029
[7]   A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients [J].
Kobashigawa, J ;
Miller, L ;
Renlund, D ;
Mentzer, R ;
Alderman, E ;
Bourge, R ;
Costanzo, M ;
Eisen, H ;
Dureau, G ;
Ratkovec, R ;
Hummel, M ;
Ipe, D ;
Johnson, J ;
Keogh, A ;
Mamelok, R ;
Mancini, D ;
Smart, F ;
Valantine, H .
TRANSPLANTATION, 1998, 66 (04) :507-515
[8]   BIOAVAILABILITY IMPROVEMENT OF MYCOPHENOLIC-ACID THROUGH AMINO ESTER DERIVATIZATION [J].
LEE, WA ;
GU, L ;
MIKSZTAL, AR ;
CHU, N ;
LEUNG, K ;
NELSON, PH .
PHARMACEUTICAL RESEARCH, 1990, 7 (02) :161-166
[9]   Impairment of mycophenolate mofetil absorption by iron ion [J].
Morii, M ;
Ueno, K ;
Ogawa, A ;
Kato, R ;
Yoshimura, H ;
Wada, K ;
Hashimoto, H ;
Takada, M ;
Tanaka, K ;
Nakatani, T ;
Shibakawa, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (06) :613-616
[10]   MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL-ALLOGRAFT RECIPIENTS [J].
SOLLINGER, HW .
TRANSPLANTATION, 1995, 60 (03) :225-232